Correction: Statement re Lincense Update

CORRECTION: PROTEOME SCIENCES TMT REAGENTS LICENSE UPDATE The following replaces the license update released on Thursday 11 August at 16:25 The full amended text appears below. The amendment is contained in the Enquiries and Notes to Editors sections For immediate release 15 August 2005 PROTEOME SCIENCES TMT REAGENTS LICENSE UPDATE The Directors of Proteome Sciences plc announce that the process of concluding a licence agreement for the company's Tandem Mass Tags® (TMT®) is continuing satisfactorily, and that a further announcement will be made when the deal is formally concluded. Enquiries: Proteome Sciences plc 01932 865065 Christopher Pearce, Chief Executive James Malthouse, Finance Director IKON Associates 01483 535102 Adrian Shaw Notes to Editors: Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has to date developed sensitive blood assays for stroke, vCJD, BSE, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions. In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoSHOP (Proteome Sciences High Output Proteomics), a toolbox that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification of potential biomarkers and drug targets. These include specialisation in membrane proteins and protein phosphorylation. The Company has also developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer, PST, qPST and TMT. The process of commercialisation is being actively pursued across the portfolio of the Company's programmes and technologies and to date licensing deals have been signed for the commercialization of tests for Stroke and TSEs. Proteome Sciences is headquartered in Cobham, Surrey in the UK and has laboratories at Kings College Hospital, London and in Frankfurt. It employs 40 full time scientists in addition to its corporate and business development staff. The Company is listed on the Alternative Investment Market. ENDS Proteome Sciences